S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
Log in
OTCMKTS:BIEI

Premier Biomedical Stock Forecast, Price & News

$0.0010
0.00 (0.00 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.00
Now: $0.00▼
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00▼
$0.01
Volume10.98 million shs
Average Volume31.09 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors. It is also developing hemp oil products, including anti-pain patch, roll-on topical products, sprays, ointments, tincture drop product, a hemp oil capsule, and pet product; sequential-dialysis technique for cancer, Alzheimer's disease, ALS, blood sepsis, leukemia, and other life-threatening cancers; and Feldetrex drug candidate for the treatment of multiple sclerosis, fibromyalgia, neuropathic pain, and traumatic brain injuries. Premier Biomedical, Inc. was founded in 2010 and is headquartered in Jackson Center, Pennsylvania.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.48 out of 5 stars


Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BIEI
Previous Symbol
CUSIPN/A
CIK1515740
Webwww.premierbiomedical.com
Phone+1-814-7868849
EmployeesN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable
$0.0010
0.00 (0.00 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIEI News and Ratings via Email

Sign-up to receive the latest news and ratings for BIEI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Premier Biomedical (OTCMKTS:BIEI) Frequently Asked Questions

How has Premier Biomedical's stock been impacted by Coronavirus?

Premier Biomedical's stock was trading at $0.0004 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BIEI stock has increased by 150.0% and is now trading at $0.0010.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Premier Biomedical?

Wall Street analysts have given Premier Biomedical a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Premier Biomedical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Premier Biomedical?

Premier Biomedical saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 40,300 shares, an increase of 122.7% from the September 30th total of 18,100 shares. Based on an average daily trading volume, of 74,333,900 shares, the short-interest ratio is currently 0.0 days.
View Premier Biomedical's Short Interest.

Who are some of Premier Biomedical's key competitors?

Some companies that are related to Premier Biomedical include (THCX.V) (THCX), 31444 (GLH), 438280 (ACG), 815446 (HC), Abacus Health Products (ABAHF), Acreage (ACRGF), Althea Group Holdings Limited (AGH.AX) (AGH), Applied Biosciences (APPB), AusCann Group Holdings Ltd (AC8.AX) (AC8), Ayr Strategies (AYRSF), Bio-Rad Laboratories (BIO), Blueberries Medical (BBM), Can B (CANB), Cannara Biotech (LOVE) and CannPal Animal Therapeutics Limited (CP1.AX) (CP1).
View all competitors.

What other stocks do shareholders of Premier Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Premier Biomedical investors own include Co-Diagnostics (CODX), Allena Pharmaceuticals (ALNA), CytoDyn (CYDY), Inovio Pharmaceuticals (INO), Sierra Oncology (SRRA), Vaxart (VXRT), MEI Pharma (MEIP), Novavax (NVAX), Rigel Pharmaceuticals (RIGL) and Selecta Biosciences (SELB).

Who are Premier Biomedical's key executives?

Premier Biomedical's management team includes the following people:
  • Mr. David Caplan, Pres, Sec., Treasurer & Director
  • Mr. Carl Eller, Marketing & Planning Vice-Pres

What is Premier Biomedical's stock symbol?

Premier Biomedical trades on the OTCMKTS under the ticker symbol "BIEI."

How do I buy shares of Premier Biomedical?

Shares of BIEI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Premier Biomedical's stock price today?

One share of BIEI stock can currently be purchased for approximately $0.00.

What is Premier Biomedical's official website?

The official website for Premier Biomedical is www.premierbiomedical.com.

How can I contact Premier Biomedical?

Premier Biomedical's mailing address is PO Box 31374, EL PASO, TX 79931-0374, United States. The company can be reached via phone at +1-814-7868849.

This page was last updated on 11/26/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.